Taken together these observations and the fact that the VDR and EAG1 are expressed in 90% and 85%; respectively, of breast cancer tumors[18–21], we hypothesized that a combined treatment targeting these two proteins in vivo could result in an improved therapeutic benefit for breast cancer management, including those tumors not treatable by hormonal therapy. The gene discussed is KCNH1; the disease is breast cancer.